Jan 08, 2024 / 06:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with BioMarin. We're very delighted to have BioMarin's new CEO, Alexander Hardy, making a presentation for the company. We're going to follow that with Q&A. If you're in the room, someone will bring you a mic, if you raise your hand for a question, you can also submit them over the portal or you can listen to me ask questions.
But with that, let me pass it over to Alexander.
Alexander Hardy - BioMarin Pharmaceutical Inc. - President, CEO & Director
Thanks very much, Jess. Good morning, everybody. As Jess said, I'm Alexander Hardy. I'm the new CEO of BioMarin. I started in the role, 1st of December 2023. Thank you very much for joining us here today. So this is our safe harbor statement. I'll be making forward-looking comments, so please look at our publicly available materials for more information.
So I
Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers